<DOC>
	<DOCNO>NCT03023748</DOCNO>
	<brief_summary>This study aim provide intravenous paritcalcitol treatment sick poor hemodialysis patient severe secondary hyperparathyroidism ( SHPT ) resistant exist vitamin D analog therapy hypercalcemia preclude use exist vitamin D analog . The study aim evaluate effect paricalcitol control SHPT , biochemical parameter chronic kidney disease-mineral bone disease , cardiac parameter , vascular calcification stiffness parameter nutrition status patient receive chronic hemodialysis treatment .</brief_summary>
	<brief_title>Intravenous Paricalcitol Chronic Hemodialysis Patients</brief_title>
	<detailed_description>This 2-year single-arm intervention study intravenous paricalcitol provide second-line treatment 30 chronic hemodialysis patient severe SHPT ( define intact parathyroid hormone [ iPTH ] ≥ 800pg/mL ) resistant exist vitamin D analog treatment ( include rocaltrol alfacalcidol ) hypercalcemia ( define serum calcium ≥2.56mmol/L ) precluding use exist vitamin D analog . The study aim evaluate control SHPT , various biochemical parameter chronic kidney disease-mineral bone disease , leave ventricular mass volume , vascular calcification stiffness parameter , handgrip strength serum albumin use intravenous paricalcitol patient receive chronic hemodialysis treatment .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Chronic hemodialysis patient severe SHPT ( define iPTH ≥ 800pg/mL ) resistant rocaltrol alfacalcidol ( define iPTH control range 2 9 time lab upper limit reference ) . Chronic hemodialysis patient severe SHPT time hypercalcemia ( define serum calcium ≥2.56mmol/L ) still &lt; 2.8mmol/L precluding use rocaltrol alfacalcidol still feasible use paricalcitol . Patients metastatic malignancy , Patients extremely poor general condition ( eg . bedbound ) expect lifespan 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>activate vitamin D treatment</keyword>
</DOC>